Literature DB >> 27112391

The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.

Peter Busch Østergren1, Caroline Kistorp2, Finn Noe Bennedbæk2, Jens Faber2, Jens Sønksen1, Mikkel Fode3.   

Abstract

Androgen deprivation therapy (ADT) induces severe hypogonadism and is associated with several adverse effects that negatively affect health and quality of life in patients with prostate cancer. ADT changes body composition characterized by an increase in fat mass and a reduction in muscle mass and strength. Insulin sensitivity is also diminished and population-based studies indicate an increased risk of diabetes mellitus and cardiovascular disease in men receiving ADT. Particularly the first 6 months of treatment seem to hold an additional risk of new cardiovascular events for patients with already existing cardiovascular disease. In this initial phase of ADT, metabolic changes are also most prominent. In addition, ADT increases the rate of bone loss and fracture risk. Currently available evidence supports the use of exercise interventions to improve physical function and mitigate ADT-induced fatigue. Some studies also indicate that exercise might moderate ADT-related changes in body composition. However, beneficial effects of exercise interventions on other ADT-related conditions have not been conclusively proven. Trials investigating the effects of ADT on fracture risk and development of diabetes mellitus and cardiovascular disease are still warranted. Furthermore, studies investigating safety and effects of physical activity in men with bone metastases are lacking.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27112391     DOI: 10.1038/nrurol.2016.67

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  111 in total

1.  Fatigue in patients with prostate cancer receiving hormone therapy.

Authors:  P Stone; J Hardy; R Huddart; R A'Hern; M Richards
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

2.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

3.  The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.

Authors:  Juan Morote; Antonio Gómez-Caamaño; José L Alvarez-Ossorio; Daniel Pesqueira; Angel Tabernero; Francisco Gómez Veiga; José A Lorente; Mariano Porras; Juan J Lobato; María J Ribal; Jacques Planas
Journal:  J Urol       Date:  2014-12-23       Impact factor: 7.450

4.  A randomized trial of aerobic versus resistance exercise in prostate cancer survivors.

Authors:  Daniel Santa Mina; M H Alibhai S; Andrew G Matthew; Crissa L Guglietti; Meysam Pirbaglou; John Trachtenberg; Paul Ritvo
Journal:  J Aging Phys Act       Date:  2012-12-10       Impact factor: 1.961

5.  Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.

Authors:  Paul L Nguyen; Ming-Hui Chen; Joshua A Beckman; Clair J Beard; Neil E Martin; Toni K Choueiri; Jim C Hu; Karen E Hoffman; Daniel E Dosoretz; Brian J Moran; Sharon A Salenius; Michelle H Braccioforte; Philip W Kantoff; Anthony V D'Amico; Ronald D Ennis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-25       Impact factor: 7.038

6.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

7.  The heart: a novel gonadotrophin-releasing hormone target.

Authors:  F Dong; D C Skinner; T John Wu; J Ren
Journal:  J Neuroendocrinol       Date:  2011-05       Impact factor: 3.627

8.  Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.

Authors:  Prue Cormie; Daniel A Galvão; Nigel Spry; David Joseph; Raphael Chee; Dennis R Taaffe; Suzanne K Chambers; Robert U Newton
Journal:  BJU Int       Date:  2014-07-27       Impact factor: 5.588

9.  Fracture risk in Danish men with prostate cancer: a nationwide register study.

Authors:  Bo Abrahamsen; Morten F Nielsen; Peter Eskildsen; Jens Thorup Andersen; Steen Walter; Kim Brixen
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

10.  Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer.

Authors:  Paul L Nguyen; Petr Jarolim; Shehzad Basaria; Jonah P Zuflacht; Jessica Milian; Samoneh Kadivar; Powell L Graham; Andrew Hyatt; Philip W Kantoff; Joshua A Beckman
Journal:  J Am Heart Assoc       Date:  2015-04-20       Impact factor: 5.501

View more
  8 in total

1.  The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.

Authors:  Peter S Kirk; Tudor Borza; Vahakn B Shahinian; Megan E V Caram; Danil V Makarov; Jeremy B Shelton; John T Leppert; Ryan M Blake; Jennifer A Davis; Brent K Hollenbeck; Anne Sales; Ted A Skolarus
Journal:  BJU Int       Date:  2017-11-28       Impact factor: 5.588

Review 2.  The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis.

Authors:  Ashley Bigaran; Eva Zopf; Jason Gardner; Andre La Gerche; Declan G Murphy; Erin J Howden; Michael K Baker; Prue Cormie
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-28       Impact factor: 5.554

3.  The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis.

Authors:  J Dalla Via; R M Daly; S F Fraser
Journal:  Osteoporos Int       Date:  2017-10-02       Impact factor: 4.507

4.  "Kicked out into the real world": prostate cancer patients' experiences with transitioning from hospital-based supervised exercise to unsupervised exercise in the community.

Authors:  Mette L K Schmidt; Peter Østergren; Prue Cormie; Anne-Mette Ragle; Jens Sønksen; Julie Midtgaard
Journal:  Support Care Cancer       Date:  2018-06-21       Impact factor: 3.603

5.  Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings.

Authors:  Aasha I Hoogland; Heather S L Jim; Brian D Gonzalez; Brent J Small; Danielle Gilvary; Elizabeth C Breen; Julienne E Bower; Mayer Fishman; Babu Zachariah; Paul B Jacobsen
Journal:  Cancer       Date:  2020-12-30       Impact factor: 6.860

6.  Synthesis of magnetic molecularly imprinted polymers with excellent biocompatibility for the selective separation and inhibition of testosterone in prostate cancer cells.

Authors:  Xiaoshuang Tang; Feng Li; Jing Jia; Chao Yang; Wei Liu; Ben Jin; Xinyang Wang; Ruixia Gao; Dalin He; Peng Guo
Journal:  Int J Nanomedicine       Date:  2017-04-12

7.  Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.

Authors:  Klara Kvorning Ternov; Jens Sønksen; Mikkel Fode; Henriette Lindberg; Caroline Michaela Kistorp; Rasmus Bisbjerg; Ganesh Palapattu; Peter Busch Østergren
Journal:  BMJ Open       Date:  2019-09-11       Impact factor: 2.692

8.  Androgen Deprivation Therapy Differentially Impacts Bone and Muscle in the Short Term in Physically Active Men With Prostate Cancer.

Authors:  Naim M Maalouf; Avneesh Chhabra; Jason Zafereo; Ross Querry; Dwight A Towler; Uma J Thakur; Joseph Frankl; John R Poindexter; Bayan Mogharrabi; May Xac; Orhan K Öz; Craig D Rubin
Journal:  JBMR Plus       Date:  2021-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.